» Articles » PMID: 36171549

Pneumococcal Vaccination Coverage in Individuals (16-59 Years) with a Newly Diagnosed Risk Condition in Germany

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2022 Sep 28
PMID 36171549
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite recommendations from the German Standing Committee on Vaccination (STIKO), pneumococcal vaccination coverage remains low in vulnerable populations. This study estimated the pneumococcal vaccination coverage rate (VCR) and timing among individuals aged 16-59 years in Germany who were recommended to receive pneumococcal vaccination, according to STIKO.

Methods: A retrospective cohort analysis was conducted using the German InGef database. Individuals aged 16 to 59 years diagnosed with at least one "at-risk" (chronic disease) or "high-risk" (e.g., immunocompromising) condition considered to be at-risk of pneumococcal infection were identified at the time of first diagnosis, between January 1, 2016 and December 31, 2018, and followed up until December 31, 2019. The percentage of cumulative pneumococcal VCR with 95% confidence interval (CI) was reported for each calendar year of follow-up.

Results: There were 334,292 individuals followed for a median of 2.38 (interquartile range (IQR) 1.63-3.13) person years. For individuals aged 16-59 years diagnosed with an incident risk condition in 2016, pneumococcal VCR increased from 0.44% (95% CI 0.41-0.48) in 2016 to 1.24% (95% CI 1.18-1.30) in 2019. In 2019, VCRs were higher in individuals with high-risk conditions compared with at-risk conditions (2.24% (95% CI 2.09-2.40) vs. 0.90% (95% CI 0.85-0.96)). In 2019, VCRs were higher in individuals aged 50 to 59 years compared with individuals aged 16 to 49 years (2.25% (95% CI 2.10-2.41) vs. 0.90% (95% CI 0.84-0.96)). Similar trends were observed in individuals with newly diagnosed risk conditions identified in 2017 and in 2018. Older age, influenza vaccination and increasing number of risk conditions increased the likelihood of pneumococcal vaccination. Median time to vaccination from diagnosis of the risk condition was shorter for high-risk conditions (369.5 days (IQR 155.8-702.0)) compared to at-risk conditions (435.5 days (IQR 196.3-758.8)).

Conclusion: Despite recommendations from STIKO, pneumococcal vaccination coverage remains very low and with long delays in vulnerable individuals aged 16-59 in Germany. Further efforts are required to increase immunization levels and shorten time to vaccination among individuals 16-59 years of age developing conditions with higher susceptibility to pneumococcal infection.

Citing Articles

Attitudes Toward General Vaccination Mediate the Association Between Influenza Vaccination History and Pneumococcal Vaccination Intention Among Older Adults in China.

Huang S, Ruan C, Jiang Y, Song Y, Zhang Y, Qin Z Vaccines (Basel). 2025; 13(1).

PMID: 39852799 PMC: 11769291. DOI: 10.3390/vaccines13010020.


Incidence of pneumococcal disease in children in Germany, 2014-2019: a retrospective cohort study.

Weaver J, Hu T, Podmore B, Barnett R, Obermuller D, Galetzka W BMC Pediatr. 2024; 24(1):755.

PMID: 39567949 PMC: 11577647. DOI: 10.1186/s12887-024-05003-7.


Outbreak of severe community-acquired bacterial infections among children in North Rhine-Westphalia (Germany), October to December 2022.

Goretzki S, van der Linden M, Itzek A, Huhne T, Adelmann R, Ala Eldin F Infection. 2024; 52(3):1099-1111.

PMID: 38366304 PMC: 11143032. DOI: 10.1007/s15010-023-02165-x.


[Pneumococcal Vaccination Coverage Rates (VCRs) Among Persons with Vaccine-Relevant Underlying Conditions and Persons Aged 60 Years and Older - An Analysis of Secondary Data from the Statutory Health Insurance (SHI) System].

Mihm S, Schelling J, Wolle R, Suck A, Hackl D, Weinke T Dtsch Med Wochenschr. 2023; 149(1-02):e1-e10.

PMID: 37875123 PMC: 10756767. DOI: 10.1055/a-2178-8306.

References
1.
Neufeind J, Betsch C, Habersaat K, Eckardt M, Schmid P, Wichmann O . Barriers and drivers to adult vaccination among family physicians - Insights for tailoring the immunization program in Germany. Vaccine. 2020; 38(27):4252-4262. DOI: 10.1016/j.vaccine.2020.04.052. View

2.
Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E . HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother. 2014; 10(6):1729-33. PMC: 5396220. DOI: 10.4161/hv.28450. View

3.
Kornum J, Thomsen R, Riis A, Lervang H, Schonheyder H, Sorensen H . Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008; 31(8):1541-5. PMC: 2494631. DOI: 10.2337/dc08-0138. View

4.
Matthews I, Lu X, Xia Q, Black W, Nozad B . Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis. BMC Public Health. 2020; 20(1):1584. PMC: 7579959. DOI: 10.1186/s12889-020-09613-5. View

5.
Castiglia P . Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther. 2014; 31(10):1011-44. PMC: 4209094. DOI: 10.1007/s12325-014-0157-1. View